US 11,091,428 B2Granted

Antiviral compounds

AssigneeHaplogen GmbH

InventorsWolfgang Fischl, Mark Whittaker, Christopher John Yarnold, Jean-Francois Pons, Mark Anthony Kerry, Patricia Leonie Amouzegh, Inaki Morao, Peter Neville Ingram, Ewa Iwona Chudyk

Life of this patent

Estimating the term…

Abstract

The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.

Claims3

Dependent claims

A compound selected from the group consisting of:

Dependencies are inferred from the claim text.

Facts

Application: 16/333,159Filed 12 Sep 2017
Priority: EP 1618855913 Sep 2016
Published: US 2019/0225575 A125 Jul 2019
Granted: 17 Aug 2021
Term ends: Not estimatedThe source records don’t support an estimate.

Classification35 codes

C07C 235/74
With the carbon atoms of the carboxamide groups bound to acyclic carbon atoms: of a saturated carbon skeleton
A61P 31/14
Antivirals: for RNA viruses
C07C 237/22
Having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton: having nitrogen atoms of amino groups…
C07C 271/24
Having oxygen atoms of carbamate groups bound to acyclic carbon atoms: with the nitrogen atom of at least one of the carbamate groups bound to a…

Family

US 2019/0225575 A1Pre-grant publication · published 25 Jul 2019
US 11,091,428 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results